Business Context and Reporting Period
Protalix Biotherapeutics, Inc. (PLX) is a commercial-stage biopharmaceutical company focused on developing and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company operates as a single segment in Israel. This summary covers the quarterly period ended June 30, 2025 (Q2 2025) and the six months ended June 30, 2025 (YTD 2025).
Key commercial products include Elelyso (taliglucerase alfa) for Gaucher disease and Elfabrio (pegunigalsidase alfa) for Fabry disease. The company partners with Pfizer for Elelyso (outside Brazil), Fiocruz for Elelyso in Brazil, and Chiesi for Elfabrio globally.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenue | $15,658 | $13,474 | $25,771 | $17,222 |
| Cost of Goods Sold | $(5,870) | $(9,456) | $(14,050) | $(12,058) |
| Gross Profit | $9,788 | $4,018 | $11,721 | $5,164 |
| Operating Income (Loss) | $1,172 | $(2,427) | $(2,973) | $(7,283) |
| Net Income (Loss) | $164 | $(2,203) | $(3,455) | $(6,798) |
| Cash and Cash Equivalents | $17,895 (as of June 30, 2025) | |||
| Short-term Bank Deposits | $15,503 (as of June 30, 2025) | |||
| Total Liquidity | $33,398 (as of June 30, 2025) | |||
| Debt | $0 (Convertible notes repaid in Sept 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 16% in Q2 2025 compared to Q2 2024, driven primarily by an $8.0 million increase in sales to Chiesi (Elfabrio). This was partially offset by a $4.7 million decrease in sales to Fiocruz (Brazil) and a $1.2 million decrease in sales to Pfizer.
- Profitability: The company reported a net income of $164,000 in Q2 2025, a significant improvement from a net loss of $2.2 million in Q2 2024. Operating income turned positive ($1.2 million) in Q2 2025 compared to a loss of $2.4 million in the prior year quarter.
- Expense Trends: Research and Development (R&D) expenses doubled in Q2 2025 ($6.0 million) compared to Q2 2024 ($3.0 million), primarily due to preparations for the Phase II clinical trial of PRX-115 (gout). Selling, General, and Administrative (SG&A) expenses decreased 26% to $2.6 million.
- Cash Flow: Net cash used in operating activities was $10.3 million for the six months ended June 30, 2025, compared to net cash provided by operations of $0.6 million in the same period in 2024. The increase in cash usage was driven by a $6.9 million increase in accounts receivable and a $1.9 million decrease in accounts payable.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash and short-term deposits ($33.4 million) are sufficient to satisfy capital needs for at least 12 months from the date of issuance.
- Financing: The company amended its Sales Agreement in March 2025 to increase the available offering size by $20.0 million. As of June 30, 2025, approximately $15.7 million remains available for sale under this agreement. The company generated $7.0 million in gross proceeds from stock sales under this agreement in the first six months of 2025.
- Product Pipeline: The company expects to commence the Phase II clinical trial for PRX-115 (uncontrolled gout) in the second half of 2025. It is also developing PRX-119 for NETs-related diseases.
- Geopolitical Risks: Operations are conducted in Israel. The filing notes ongoing military conflicts involving Hamas, Hezbollah, and Iran. While the company is designated an "essential enterprise" and has stored drug substance in multiple locations to mitigate risk, the duration and severity of the conflict remain unpredictable.
- Tax Legislation: New U.S. tax reform legislation (H.R.1) enacted on July 4, 2025, restores deductibility for domestic research expenditures. The company is evaluating the impact on its financial statements.
Key Facts for Investor Verification
- Revenue Concentration: Verify the sustainability of revenue growth from Chiesi, which drove the majority of the increase, while sales to Fiocruz (Brazil) declined significantly.
- Cash Burn Rate: Monitor the shift from positive operating cash flow in 2024 to negative operating cash flow in 2025, driven by working capital changes (increased receivables) and higher R&D spend.
- Debt Status: Confirm the company remains debt-free following the full repayment of 2024 Convertible Notes in September 2024.
- Equity Dilution: Track the utilization of the At-The-Market (ATM) Sales Agreement, which remains a primary source of liquidity but may lead to shareholder dilution.
- Geopolitical Exposure: Assess the potential impact of the ongoing conflict in Israel on manufacturing continuity and supply chain logistics, despite current operational stability.